Several reports have suggested that EPO and EPO stimulating agents could promote tumor cell proliferation through its specific receptor (EPOR) and hypoxia in head and neck tumors [39], breast cancer [40] and HCC [41]. The gene discussed is EPO; the disease is hepatocellular carcinoma.